To the Moon or to the Bubble? The Space Race, the AI Boom, and the New Competition for Power
Student Journal of Business and Economics · 15.11.2026 · 21
DOI: 10.67521/sjbe.2026.041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Student Journal of Business and Economics, online erschienen am 15.11.2026. Verfasst von Mark Mark Anikandrov. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
The drive to explore is in everyone’s hearts, fueled by adrenaline from being challenged in difficult situations and by the realization of how much people have achieved during the 20th and 21st centuries. The 20th-century Space Race was about being a leader and establishing dominance in space. However, the 21st century is all about Artificial Intelligence (AI); it is growing day by day. Individuals, businesses, and governments are pouring billions, if not trillions, of dollars into AI to achieve different goals. SpaceX and Blue Origin are competing to capture a larger market share in the space field, developing and improving the commercial space industry. This article will include an analysis of investment decisions between Artificial Intelligence giants like NVIDIA and Google and Space Industry professionals like SpaceX. So the question is, if you had a billion dollars, where would you invest your money: to the Moon or to the Bubble?
Zitieren
APA
Anikandrov, M. M. (2026). To the Moon or to the Bubble? The Space Race, the AI Boom, and the New Competition for Power. Student Journal of Business and Economics, 21. https://doi.org/10.67521/sjbe.2026.041
Vancouver
Anikandrov MM. To the Moon or to the Bubble? The Space Race, the AI Boom, and the New Competition for Power. Student Journal of Business and Economics. 2026:21. doi:10.67521/sjbe.2026.041
BibTeX
@article{Anikandrov2026,
author = {Anikandrov, Mark Mark},
title = {To the Moon or to the Bubble? The Space Race, the AI Boom, and the New Competition for Power},
journal = {Student Journal of Business and Economics},
year = {2026},
pages = {21},
doi = {10.67521/sjbe.2026.041}
}
EUVIMED